

Marko Skelin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8503682/publications.pdf>

Version: 2024-02-01

39
papers

465
citations

840585

11
h-index

713332

21
g-index

39
all docs

39
docs citations

39
times ranked

736
citing authors

#	ARTICLE	IF	CITATIONS
1	The requirements of a specialist breast centre. <i>Breast</i> , 2020, 51, 65-84.	0.9	111
2	Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. <i>Clinical Therapeutics</i> , 2017, 39, 378-403.	1.1	81
3	Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-Risk Myelodysplastic Syndromes. <i>Annals of Internal Medicine</i> , 2020, 173, 595.	2.0	58
4	Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. <i>International Journal of Cardiology</i> , 2020, 301, 90-95.	0.8	27
5	Once-Weekly Semaglutide in Adults with Overweight or Obesity. <i>New England Journal of Medicine</i> , 2021, 385, e4.	13.9	24
6	Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 126-133.	1.0	22
7	Effect of timing of levothyroxine administration on the treatment of hypothyroidism: a three-period crossover randomized study. <i>Endocrine</i> , 2018, 62, 432-439.	1.1	20
8	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. <i>Annals of Medicine</i> , 2017, 49, 51-62.	1.5	17
9	Survival analysis, more than meets the eye. <i>Biochemia Medica</i> , 2017, 27, 14-18.	1.2	17
10	Elevated Neutrophil-Lymphocyte-ratio and Platelet-Lymphocyte Ratio in Myelofibrosis: Inflammatory Biomarkers or Representatives of Myeloproliferation Itself?. <i>Anticancer Research</i> , 2018, 38, 3157-3163.	0.5	16
11	Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG1016 and De-ESCALaTE. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 1275-1281.	0.8	13
12	Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , 2021, 384, 776-779.	13.9	12
13	The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. <i>International Journal of Clinical Practice</i> , 2018, 72, e13274.	0.8	6
14	Liraglutide in Children and Teens with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1786-1787.	13.9	6
15	Aspirin Use and the Risk of Cancer. <i>JAMA Oncology</i> , 2019, 5, 912.	3.4	6
16	De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 4599-4603.	0.8	5
17	The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes. <i>European Heart Journal</i> , 2020, 41, 325-325.	1.0	4
18	Platelet Counts and Risk of Major Bleeding With Ibrutinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e399.	0.2	3

#	ARTICLE	IF	CITATIONS
19	Dietary Supplement Use and Patient Outcomes in High-Risk Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2110-2110.	0.8	3
20	The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis. <i>Journal of Chemotherapy</i> , 2022, , 1-8.	0.7	3
21	Risk stratification according to insulin type. <i>European Journal of Heart Failure</i> , 2018, 20, 1497-1497.	2.9	2
22	Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2583-2584.	0.8	2
23	The economic impact of a clinical pharmacist's involvement in the hospital medicines policy in a rural area. <i>International Journal of Clinical Practice</i> , 2021, 75, e14859.	0.8	2
24	Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. <i>Leukemia</i> , 2019, 33, 2554-2554.	3.3	1
25	Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association. <i>JAMA Oncology</i> , 2019, 5, 1642.	3.4	1
26	Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 442.	3.4	1
27	Dabigatran Use Associated with Hemopericardium and Hemothorax. <i>Collegium Antropologicum</i> , 2020, 44, 155-158.	0.1	1
28	Comparison of media and academic attention of recently published positive and neutral or negative randomized cardiovascular clinical trials. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 1.	0.5	1
29	Radiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dilemma finally resolved. An updated meta-analysis. <i>Annals of Oncology</i> , 2019, 30, v457.	0.6	0
30	Catheter Ablation Compared With Drug Therapy for Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1105.	3.8	0
31	In reply to Swain et al.: Re-evaluation of updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2113-2114.	0.8	0
32	An observational, multicentre study on different insulin glargine U100 titration algorithms used in patients with type 2 diabetes in daily medical practice in Adriatic countries: The ADRESA study. <i>Diabetes Research and Clinical Practice</i> , 2019, 150, 144-149.	1.1	0
33	Dyslipidaemia, a factor worthy of adjustment. <i>European Journal of Heart Failure</i> , 2020, 22, 564-564.	2.9	0
34	On interactions between body mass index, type of anticoagulation and outcomes. <i>International Journal of Cardiology</i> , 2020, 312, 107.	0.8	0
35	Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> 2019;42:1912-1920. <i>Diabetes Care</i> , 2020, 43, e28-e29.	4.3	0
36	Effect of statin therapy on cancer incidence. <i>Endocrine Oncology and Metabolism</i> , 2016, 2, 250-257.	0.0	0

#	ARTICLE	IF	CITATIONS
37	PF340 PATIENTS WITH HIGHER BODY MASS INDEX TREATED WITH DIRECT / NON VITAMIN K DEPENDENT ANTICOAGULANTS (DOAC / NOAC) EXPERIENCE WORSE CLINICAL OUTCOMES. HemaSphere, 2019, 3, 122.	1.2	0
38	Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases. JAMA - Journal of the American Medical Association, 2022, 327, 1505.	3.8	0
39	Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate. Annals of Hematology, 2022, , 1.	0.8	0